AFIB · As filed with the SEC

Acutus Medical income statement, by quarter

The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts

USD thousands, except per-share amounts	Q4 2024^† 3 months ended Dec 31, 2024	Q3 2024 3 months ended Sep 30, 2024	Q2 2024 3 months ended Jun 30, 2024	Q1 2024 3 months ended Mar 31, 2024	Q4 2023^† 3 months ended Dec 31, 2023
Revenue	7,130^†	5,266	4,127	3,625	2,348^†
Cost of products sold	6,125^†	4,894	4,470	3,655	2,466^†
Gross profit (loss)	1,005^†	372	(343)	(30)	(118)^†
Operating expenses (income):
Research and development	0^†	0	0	0	730^†
Selling, general and administrative	2,556^†	2,318	2,225	3,337	4,564^†
Change in fair value of contingent consideration	0^†	0	0	0	0^†
Gain on sale of business	(2,718)^†	(2,435)	(2,869)	(2,792)	(3,153)^†
Total operating expenses	1,286^†	(117)	(644)	545	2,141^†
Loss from operations	(281)^†	489	301	(575)	(2,259)^†
Other income (expense):
Change in fair value of warrant liability	108^†	(174)	564	(283)	1,459^†
Interest income	—	—	—	281	—
Interest expense	—	—	—	(1,478)	—
Interest income	122^†	153	207	—	365^†
Interest expense	(1,374)^†	(1,395)	(1,510)	—	(1,545)^†
Other revenue	—	111	76	—	—
Total other expense, net	(1,030)^†	(1,305)	(663)	(1,480)	279^†
Loss from continuing operations before income taxes	(1,311)^†	(816)	(362)	(2,055)	(1,980)^†
Income tax expense	—	—	—	0	—
Net loss from continuing operations	(1,311)^†	(816)	(362)	(2,055)	(2,043)^†
Discontinued operations:
Loss from discontinued operations before income taxes	(93)^†	(4,791)	(552)	445	(31,585)^†
Income tax expense - discontinued operations	2^†	0	0	(10)	137^†
Loss from discontinued operations	(95)^†	(4,791)	(552)	435	(31,722)^†
Net loss	(1,406)^†	(5,607)	(914)	(1,620)	(33,765)^†
Other comprehensive income (loss):
Unrealized gain on marketable securities	0^†	0	0	0	0^†
Foreign currency translation adjustment	113^†	(15)	0	0	87^†
Comprehensive loss	(1,293)^†	(5,622)	(914)	(1,620)	(33,678)^†
Net loss per share, basic and diluted:
Loss from continuing operations, basic (in dollars per share)	—	(0.03)	(0.01)	(0.07)	—
Loss from discontinued operations, basic (in dollars per share)	—	(0.16)	(0.02)	0.01	—
Net loss per common share, basic (in dollars per share)	—	(0.19)	(0.03)	(0.06)	—
Net earnings (loss) per share, diluted:
Loss from continuing operations, (in dollars per share)	—	(0.03)	(0.01)	(0.07)	—
Loss from discontinued operations , diluted (in dollars per share)	—	(0.16)	(0.02)	0.01	—
Net loss per common share, diluted (in dollars per share)	—	(0.19)	(0.03)	(0.06)	—
Weighted average number of common shares outstanding, basic (in shares)	—	29,799,241	29,721,542	29,693,926	—
Weighted average number of common shares outstanding, diluted- continuing operations (in shares)	—	29,799,241	29,721,542	29,693,926	—

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.